923 Virtual Biopsy in Oncology: A Paradigm Shift in Cancer Diagnosis and Management

Abstract

Aim
The aim of this review is to evaluate virtual biopsy technologies, including liquid biopsy, advanced imaging, and AI, in improving cancer diagnostics, monitoring disease progression, and enabling personalized treatments, while identifying challenges such as standardization, clinical validation, and integration into oncology practice.

Method
The literature search was conducted across several databases, including PubMed, EMBASE, Google Scholar, the Cochrane Library, and Scopus, using key terms related to the oncological basis of virtual biopsy. Additional sources were identified through manual examination of references in recent reviews and articles focusing on the impact of virtual biopsy and related technological advancements in oncology.

Results
Virtual biopsy enables real-time monitoring of tumour progression and personalized treatment planning, with applications demonstrated in cancers like glioblastoma. Radiomics and radiogenomics improve tumour characterization, while AI enhances diagnostic accuracy. The development of hybrid models that integrate radiomics with genomics and clinical data provides a more comprehensive understanding of the disease. Which enables clinicians to devise treatment plans that are more effective with fewer side effects.

Conclusions
Virtual biopsy is navigating a transformative path, promising to redefine the precision in cancer diagnosis and the customization of surgical treatment strategies. This evolution leans on advancements in radiomics and artificial intelligence, aiming to offer more non-invasive diagnostic options. With challenges in ensuring accessibility and addressing ethical and data security concerns, collaborative efforts across disciplines are key to navigating these complexities. As virtual biopsy continues to mature, it is poised to enhance patient outcomes, representing a major leap towards personalised cancer care.